InvestSMART

Memphasys Limited (ASX:MEM)

ALERT: Price-sensitive ASX Announcement for MEM
Current share price for MEM : $0.008 0.004 (100%)+
Announcement
Release
28 Oct 2025 8:37AM
Price at Release
$0.004
Full Release
download
Summary
Memphasys Limited has signed a non-exclusive supply agreement with the Andrology Center Coimbatore in India, marking the first Indian distribution agreement under its go-direct commercial strategy. This partnership aims to accelerate the adoption and distribution of the Felix™ System, a sperm separation technology, across a network of more than 200 IVF clinics in India. The agreement follows a temporary pause in sales due to a regulatory reclassification of the Felix™ System as a medical device in 2022. With anticipated regulatory approvals by early 2026, this initiative re-establishes Memphasys' presence in the Indian market and reflects the company's strategy to convert clinical relationships into structured commercial partnerships to drive revenue and growth. The agreement includes a commitment from the Andrology Center to purchase a minimum of 1,800 Felix™ cartridges in the first year and at least 2,700 in the second year, post-approvals. This strategic move strengthens Memphasys' global commercial footprint as it continues to expand into new jurisdictions.
Key Points
  • Memphasys signs non-exclusive supply agreement with Andrology Center Coimbatore.
  • Go-direct strategy replaces distributor-led approach for Indian market.
  • Agreement includes Year 1 commitment of 1,800 Felix™ cartridges.
  • Regulatory reclassification in 2022 temporarily paused sales.
  • Partnership follows successful clinical validation milestones.
  • CE Mark and Indian CDSCO approvals expected by early 2026.
  • Strategic focus on converting clinical relationships into commercial partnerships.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.